In line with the strategy for its Business Unit Healthcare to drive growth in higher value segments, including medical devices, DKSH has partnered with Creative Biosciences to distribute and grow sales of a new non-invasive colorectal cancer detection solution in Thailand.
Media release
Bangkok, May 6, 2021 – DKSH Business Unit Healthcare, the leading partner for healthcare companies seeking to grow their business in Asia and beyond, has signed an agreement with Creative Biosciences (Guangzhou) Co., Ltd., the leading advanced biotech enterprise in the in vitro diagnostics (IVD) and point-of-care testing (POCT) industries. As part of the agreement, DKSH will provide full-agency services, including marketing and sales, warehousing as well as distribution and logistics, for Creative Biosciences' Colosafe ®; the first NMPA approved in China and second of its kind in the world with CE mark and ISO13485 certificate.
The goal of this partnership is to grow public awareness and market sales of Colosafe®, a kit for early detection of colorectal cancer by performing series of steps including stool sample preparation, DNA extraction and conversion, real-time quantitative methylation-specific polymerase chain reaction (qMSP), and outcome report and interpretation. By leveraging DKSH's distribution and commercial capabilities, more GI doctors and laboratory technicians nationwide can have access to this premium device and better support their patients with advanced technology of colorectal cancer detection.
“We are extremely excited about our relationship with DKSH Thailand. This is a win-win co-operation for both sides.” said Mr. Leo Liao, Chief Operating Officer of CreativeBio. “Thanks to DKSH's remarkable expertise in the promotion of medical devices, I am positively confident that the provision of our best-in-class IVD products to healthcare professionals will certainly advance and shape clinical practice in cancer diagnosis with the unparalleled clinical performance of our products in Thailand. The long-term vision of this partnership is to save lives in Thailand and Asia.”
John Clare, Vice President, Healthcare, DKSH Thailand & Indochina, said: “Our partnership with Creative Biosciences demonstrates our commitment to providing Thai patients with high-quality medical devices. Our broad reach across the medical channel as well as our structured market development approach will help drive market share for Colosafe® in Thailand, thus offering improved access to advanced cancer detection solutions and consequently better treatment options for Thai patients.”
For further information, please contact:
DKSH Business Unit Healthcare
Sheena Flannery
Director, Group Communications
Phone +66 2 220 9739
sheena.flannery@dksh.com
About Creative Biosciences (Guangzhou) Co., Ltd.
CreativeBio was founded in January 2015. It has evolved an advanced bio-tech enterprise specializing in noninvasive cancer detection kits (including device, reagent, and equipment) and POCT products. Colosafe® is a featured IVD product which has been implemented in over 500 major top hospitals covering almost all provincial areas in China by far. As a leading benchmark company in the industry with world class R&D team, CreativeBio has engaged early detection kits for lung, bladder, cervical, liver cancers and other POCT products actively in the development to enrich its pipelines of which some will be ready for market in the next couple years. https://en.creativebio.cn/
About DKSH
At DKSH, our purpose is to enrich people’s lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our Business Units Healthcare, Consumer Goods, Performance Materials and Technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 32,450 specialists, generating net sales of CHF 10.7 billion in 2020. The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices. With around 7,970 specialists, the Business Unit generated net sales of CHF 5.4 billion in 2020. www.dksh.com/hec